Celgene pulls EU application for anemia-drug approval

06/2/2008 | Boston Globe (tiered subscription model), The · Reuters

The European Medicines Agency has again declined to recommend approval for Celgene's Revlimid, prompting the company to withdraw its application to market the anemia drug for transfusion-dependent patients with myelodysplastic syndromes. The drugmaker said it will not abandon plans to seek approval for the indication in Europe despite the agency's negative review.

View Full Article in:

Boston Globe (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Fridley, MN
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC